DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE

流感病毒疫苗小分子双佐剂体系的研制

• 批准号: 10935796
• 负责人: JENNIFER LAPEK
• 金额: $ 247.18万
• 依托单位: SCRIPPS INSTITUTION OF OCEANOGRAPHY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2028-09-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10935796
• 关键词: Adjuvant; Agonist; Animal Model; Animals; Chronic Disease; Clinical Trials; Communicable Diseases; Contractor; Development; Drug Kinetics; Elderly; Fluzone; Formulation; Frequencies; Human; Immune; Immunization; Individual; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B Virus; Modeling; Mus; Patients; Prevention; Route; Structure-Activity Relationship; Support Contracts; System; TLR4 gene; TLR7 gene; Toxicology; Vaccine Adjuvant; Vaccines; aged; cross immunity; dosage; efficacy study; immunogenicity; improved; influenza virus strain; influenza virus vaccine; influenzavirus; manufacture; novel vaccines; protective efficacy; safety study; seasonal influenza; small molecule

“Prevention is better than cure”, is the motive behind the vaccines for infectious diseases. Current vaccines for influenza need help as they are only effective for short durations, particularly in elderly individuals and patients with chronic diseases. Also, new vaccines must be prepared yearly to protect against new strains of influenza virus. Thus, there is substantial demand for the development of new immune boosting adjuvants to improve existing influenza vaccines. Our contract supports the development of a new vaccine adjuvant, Fos47, that improves vaccines durability and cross-protection in animal models. The protective efficacy of vaccine adjuvant Fos47 will be assessed in influenza virus challenge models to identify an optimal dosage, route and frequency of immunization. The vaccine adjuvant will be prepared in a large scale for the initiation of human clinical trials.

“预防胜于治疗”是传染病疫苗背后的动机，因为它们只能在短期内有效，特别是对于老年人和慢性病患者。此外，还必须准备新的疫苗。因此，对开发新的免疫增强佐剂以改进现有流感疫苗有很大的需求，我们的合同支持开发一种新的疫苗佐剂 Fos47，该佐剂可提高疫苗的耐久性和交叉作用。保护于疫苗佐剂Fos47的保护效果将在流感病毒攻击模型中进行评估，以确定最佳的免疫剂量、途径和频率，并将大规模制备疫苗佐剂以启动人体临床试验。